Nucleoside/nucleotide reverse transcriptase inhibitor sparing regimen with once daily integrase inhibitor plus boosted darunavir is non-inferior to standard of care in virologically-suppressed children and adolescents living with HIV – Week 48 results of the randomised SMILE Penta-17-ANRS 152 clinical trial

05 Jun, 2023

Authors: Compagnucci A, Chan KM, Saïdi Y, Cressey RT, Bamford A, Riault Y, Coelho A, Nolan A, Chalermpantmetagul S, Morkunaite G, Amuge P, Musiime V, Violari V, Cotton M, Kekitiinwa RA, Kaudha E, Groenewald M, Liberty AA, Kanjanavanit S, Volokha A, Bologna R, Ruz PN, Tato PL, Paioni P, Marques L, Reliquet V, Niehues T, Welch BS, Ford D, Giaquinto C, Gibb MD, Babiker A, Amador RTJ, SMILE-PENTA17-ANRS 152 Trial Group

Published in: eClinicalMedicine